Belpointe Asset Management LLC Bristol Myers Squibb CO Transaction History

Belpointe Asset Management LLC

$1.28 Billion
Q2 2024

A detailed history of Belpointe Asset Management LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Belpointe Asset Management LLC holds 189,429 shares of BMY stock, worth $9.8 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares

189,429

Previous 183,425 3.27%

Holding current value

$9.8 Million

Previous $9.95 Million 20.92%

% of portfolio

0.61%

Previous 0.8%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$40.25 - $52.99 $241,661 - $318,151	6,004 Added 3.27%	189,429 $7.87 Million
Q1 2024 May 08, 2024	BUY	$47.98 - $54.4 $1.19 Million - $1.35 Million	24,803 Added 15.64%	183,425 $9.95 Million
Q4 2023 Feb 13, 2024	SELL	$48.48 - $57.85 $161,680 - $192,929	-3,335 Reduced 2.06%	158,622 $8.14 Million
Q3 2023 Nov 15, 2023	SELL	$57.89 - $64.73 $15,456 - $17,282	-267 Reduced 0.16%	161,957 $9.4 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $439,981 - $488,530	6,906 Added 4.45%	162,224 $10.4 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $330,521 - $374,885	5,030 Added 3.35%	155,318 $10.8 Million
Q4 2022 Feb 08, 2023	BUY	$68.48 - $81.09 $65,466 - $77,522	956 Added 0.64%	150,288 $10.8 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $297 - $175,963	2,290 Added 1.56%	149,332 $10.6 Million
Q2 2022 Aug 02, 2022	SELL	$72.62 - $79.98 $1.42 Million - $1.57 Million	-19,607 Reduced 11.77%	147,042 $11.3 Million
Q1 2022 Apr 28, 2022	BUY	$61.48 - $73.72 $646,708 - $775,460	10,519 Added 6.74%	166,649 $12.2 Million
Q4 2021 Feb 15, 2022	SELL	$53.63 - $62.52 $71,059 - $82,839	-1,325 Reduced 0.84%	156,130 $9.74 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $191,237 - $224,009	3,232 Added 2.1%	157,455 $9.32 Million
Q2 2021 Aug 09, 2021	SELL	$61.91 - $67.42 $5.49 Million - $5.98 Million	-88,637 Reduced 36.5%	154,223 $10.3 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $1.87 Million - $2.11 Million	31,593 Added 14.95%	242,860 $15.3 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $1.05 Million - $1.19 Million	18,133 Added 9.39%	211,267 $13.1 Million
Q3 2020 Nov 13, 2020	SELL	$57.43 - $63.64 $147,422 - $163,363	-2,567 Reduced 1.34%	189,128 $10.5 Million
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $230,064 - $254,941	4,006 Added 2.12%	193,134 $11.6 Million
Q2 2020 Jul 20, 2020	BUY	$54.82 - $64.09 $140,722 - $164,519	2,567 Added 1.36%	191,695 $11.3 Million
Q1 2020 Jul 20, 2020	BUY	$46.4 - $67.43 $733,769 - $1.07 Million	15,814 Added 9.12%	189,128 $10.5 Million
Q4 2019 Feb 18, 2020	BUY	$49.21 - $64.19 $557,303 - $726,951	11,325 Added 6.99%	173,314 $11.1 Million
Q3 2019 Jan 16, 2020	SELL	$42.77 - $50.71 $18,091 - $21,450	-423 Reduced 0.26%	161,989 $8.21 Million
Q2 2019 Nov 22, 2019	SELL	$44.62 - $49.34 $205,876 - $227,654	-4,614 Reduced 2.76%	162,412 $0
Q1 2019 Jun 11, 2019	SELL	$45.12 - $53.8 $6,632 - $7,908	-147 Reduced 0.09%	167,026 $7.97 Million
Q4 2018 Mar 06, 2019	SELL	$48.76 - $63.23 $215,763 - $279,792	-4,425 Reduced 2.58%	167,173 $8.69 Million
Q3 2018 Nov 23, 2018	BUY	$55.19 - $62.25 $649,365 - $732,433	11,766 Added 7.36%	171,598 $10.7 Million
Q2 2018 Aug 06, 2018	BUY	$50.53 - $62.98 $27,185 - $33,883	538 Added 0.34%	159,832 $8.85 Million
Q1 2018 Aug 06, 2018	SELL	$59.92 - $68.98 $206,004 - $237,153	-3,438 Reduced 2.11%	159,294 $10.1 Million
Q4 2017 Feb 15, 2018	SELL	$59.94 - $65.35 $69,170 - $75,413	-1,154 Reduced 0.7%	162,732 $9.97 Million
Q3 2017 Nov 16, 2017	BUY	$55.23 - $63.74 $9.05 Million - $10.4 Million	163,886	163,886 $10.4 Million

Others Institutions Holding BMY

# of Institutions

2,402

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $110B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Belpointe Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Belpointe Asset Management LLC with notifications on news.

Account

Belpointe Asset Management LLC Bristol Myers Squibb CO Transaction History